Form 4 SIGMA TAU FINANZIARIA For: Sep 24 (10K)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:		3235-0287
Expires:	February 28, 2011
Estimated average burden
hours per response		0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

SIGMA TAU FINANZIARIA SPA

(Last)

(First)

(Middle)

VIA SUDAFRICA, 20,

(Street)

ROME

00144

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
DOR BIOPHARMA INC [DORB]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2009

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/24/2009		P		3,952,569	A	$ 0.253	45,619,236	I ⁽¹⁾	Indirect ⁽¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Common Stock Warrant (right to buy)

$ 0.278

09/24/2009

J⁽²⁾

09/27/2009

09/27/2014⁽³⁾

Common Stock

1,976,284

$ 0

I ⁽²⁾

Indirect ⁽²⁾

1. Name and Address of Reporting Person^*

SIGMA TAU FINANZIARIA SPA

(Last)

(First)

(Middle)

VIA SUDAFRICA, 20

(Street)

ROME

00144

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

SIGMA TAU INTERNATIONAL SA

(Last)

(First)

(Middle)

19-21 BLVD. DU PRINCE HENRI

(Street)

L-1724 LUXEMBOURG

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Sigma-Tau America S.A.

(Last)

(First)

(Middle)

19-21 BLVD. DU PRINCE HENRI

(Street)

L-1724 LUXEMBOURG

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Sigma-Tau Pharmaceuticals, Inc.

(Last)

(First)

(Middle)

9841 WASHINGTONIAN BLVD, SUITE 500

(Street)

GAITHERSBURG

20878

(City)

(State)

(Zip)

Explanation of Responses:
1. Shares directly owned by Sigma-Tau Pharmaceuticals, Inc. (?Pharmaceuticals?). Pharmaceuticals is a direct wholly-owned subsidiary of Sigma-Tau America S.A. (?America?). America is a direct wholly-owned subsidiary of Sigma-Tau International S.A. (?International?). International is a direct wholly-owned subsidiary of Sigma-Tau Finanziaria S.p.A.
2. This warrant was issued by the Issuer to Pharmaceuticals in consideration of Pharmaceuticals? purchase of 3,952,569 shares of common stock on September 24, 2009.
3. The expiration date of the warrant may be accelerated at the Issuer?s option if the Issuers?s common stock meets certain price thresholds and the common shares underlying the warrant are registered for resale pursuant to an effective registration statement or are freely transferable without volume restrictions pursuant to Rule 144 under the Securities Act of 1933, as amended.
Remarks: Exhibit List Exhibit 99 - Joint Filer Information

	/s/ Maurizio Terenzi, Proxy-holder authorized	09/28/2009
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

EX-99.1

Unassociated Document

Exhibit 99

Joint Filer Information

Name:	Sigma-Tau International S.A.

Address:
	19-21 Boulevard du Prince Henri
	L-1724 Luxembourg

Designated Filer:	Sigma-Tau Finanziaria S.p.A.

Issuer & Ticker Symbol:	DOR BioPharma, Inc. (DORB)

Date of Earliest
Transaction Required
to be Reported:	9/24/09

Signature:	/s/ Gregg Lapointe
	Name: Gregg Lapointe
	Title: Attorney-in-fact
	SIGMA-TAU INTERNATIONAL S.A.

Name:	Sigma-Tau America S.A.

Address:	19-21 Boulevard du Prince Henri
	L-1724 Luxembourg

Designated Filer:	Sigma-Tau Finanziaria S.p.A.

Issuer & Ticker Symbol:	DOR BioPharma, Inc. (DORB)

Date of Earliest
Transaction Required
to be Reported:	9/24/09

Signature:	/s/ Gregg Lapointe
	Name: Gregg Lapointe
	Title: Attorney-in-fact
	SIGMA-TAU AMERICA S.A.

Name:	Sigma-Tau Pharmaceuticals, Inc.

Address:	9841 Washingtonian Blvd, Suite 500
	Gaithersburg, Maryland 20878
	USA

Designated Filer:	Sigma-Tau Finanziaria S.p.A.

Issuer & Ticker Symbol:	DOR BioPharma, Inc. (DORB)

Date of Earliest
Transaction Required
to be Reported:	9/24/09

Signature:	/s/ Gregg Lapointe
	Name: Gregg Lapointe
	Title: Chief Executive Officer
	SIGMA-TAU PHARMACEUTICALS, INC.

Add to Delicious

Digg It

Send by Email

View Comments (0)

Post Comment